EULAR Textbook on Rheumatic Diseases

1 EULAR Textbook on Rheumatic Diseases References chapter 23 1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23(5):581-90. 2. Poormoghim H, Lucas M, Fertig N, Medsger TA, Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000;43(2):444-51. 3. Mayes MD, Lacey JV, Jr., Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

2 Arthritis Rheum 2003;48(8):2246-55. 4. Czirjak L, Kiss CG, Lovei C, Suto G, Varju C, Fuzesi Z, et al. Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol 2005;23(6):801-8. 5. Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004;43(5):596-602. 6. Kettaneh A, Al Moufti O, Tiev KP, Chayet C, Toledano C, Fabre B, et al. Occupational exposure to solvents and gender-related risk of systemic sclerosis: a metaanalysis of case-control studies.

3 J Rheumatol 2007;34(1):97-103. 7. Bovenzi M, Barbone F, Pisa FE, Betta A, Romeo L, Tonello A, et al. A case-control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ Health 2004;77(1):10-6. 8. Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune Diseases . Environ Health Perspect 1999;107 Suppl 5:743-8. 9. Diot E, Lesire V, Guilmot JL, Metzger MD, Pilore R, Rogier S, et al. Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med 2002;59(8):545-9. 10. Garabrant DH, Lacey JV, Jr., Laing TJ, Gillespie BW, Mayes MD, Cooper BC, et al.

4 Scleroderma and solvent exposure among women. Am J Epidemiol 2003;157(6):493-500. EULAR Textbook on Rheumatic Diseases 11. Jimenez SA, Artlett CM. Microchimerism and systemic sclerosis. Curr Opin Rheumatol 2005;17(1):86-90. 12. Hamamdzic D, Kasman LM, LeRoy EC. The role of infectious agents in the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2002;14(6):694-8. 13. Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001;19(1):4-8. 14. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002;4(2):99-107.

5 15. Allanore Y, Dieude P, Boileau C. Updating the genetics of systemic sclerosis. Curr Opin Rheumatol. 16. Jungel A, Ospelt C, Gay S. What can we learn from epigenetics in the year 2009? Curr Opin Rheumatol;22(3):284-92. 17. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2003;2(4):181-91. 18. Neidhart M, Kuchen S, Distler O, Bruhlmann P, Michel BA, Gay RE, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 1999;42(2):389-92. 19. Jimenez SA, Diaz A, Khalili K. Retroviruses and the pathogenesis of systemic sclerosis.

6 Int Rev Immunol 1995;12(2-4):159-75. 20. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998;338(17):1186-91. 21. Artlett CM. Microchimerism and scleroderma: an update. Curr Rheumatol Rep 2003;5(2):154-9. 22. Nelson JL. Microchimerism and HLA relationships of pregnancy: implications for autoimmune Diseases . Curr Rheumatol Rep 2001;3(3):222-9. 23. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22(4):675-94. 24. Renaudineau Y, Revelen R, Levy Y, Salojin K, Gilburg B, Shoenfeld Y, et al. Anti-endothelial cell antibodies in systemic sclerosis.

7 Clin Diagn Lab Immunol 1999;6(2):156-60. 25. Kahaleh B. Lymphocyte interactions with the vascular endothelium in systemic sclerosis. Clin Dermatol 1994;12(3):361-7. EULAR Textbook on Rheumatic Diseases 26. Kahaleh MB. Vascular involvement in systemic sclerosis (SSc). Clin Exp Rheumatol 2004;22(3 Suppl 33):S19-23. 27. Gruschwitz MS, Hornstein OP, von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995;38(2):184-9. 28. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S.

8 Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005;24(2):111-6. 29. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27(1):155-60. 30. Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A. Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 2007;25(1):60-6. 31.

9 Avouac J, Juin F, Wipff J, Couraud PO, Chiocchia G, Kahan A, et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis 2008;67(10):1455-60. 32. Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C, et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006;54(8):2605-15. 33. Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.

10 Arthritis Rheum 2007;56(6):1994-2004. 34. Butler AR, Flitney FW, Williams DL. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci 1995;16(1):18-22. 35. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994;21(8):1477-83. 36. Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y. High DNA oxidative damage in systemic sclerosis. J Rheumatol;37(12):2540-7. EULAR Textbook on Rheumatic Diseases 37.